Improving the safety and continuity of medicines management at care transitions

Bradford Teaching Hospitals NHS Foundation Trust0 个研究点目标入组 1,641 人开始时间: 2018年4月11日最近更新: 2023年9月18日

适应症

试验速览

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35487708/ (added 12/08/2022)

•1. Admitted or transferred to a ward participating in the ISCOMAT trial
•2. Heart failure with evidence of at least moderate left ventricular systolic dysfunction confirmed (via echocardiogram) within the last 5 years
•3. Aged 18 years or over at time of admission to hospital
•4. Planned discharged from recruiting hospital to their home (defined by usual place of residence) or a care home
•5. Planned discharge to within geographical area of that cluster
•6. Capacity to provide Informed Consent
•7. Provide informed consent

•NHS Trusts meeting any of the following exclusion criteria will not be eligible for inclusion:
•1. Already providing medicines management deemed to be sufficiently similar to the MaTI intervention
•Patients meeting any of the following exclusion criteria will not be eligible for inclusion:
•1. Patients in a terminal phase of illness / end of life care pathway who are not expected to survive beyond 6 weeks from date of discharge
•2. Patients who are already participating in the ISCOMAT study (for example, patients who have been re-admitted)

发起方